DE69632681D1 - Lymphotoxin-alpha/beta komplexe und antikörper gegen den lymphotoxin-beta rezeptor als agenzien gegen tumoren - Google Patents
Lymphotoxin-alpha/beta komplexe und antikörper gegen den lymphotoxin-beta rezeptor als agenzien gegen tumorenInfo
- Publication number
- DE69632681D1 DE69632681D1 DE69632681T DE69632681T DE69632681D1 DE 69632681 D1 DE69632681 D1 DE 69632681D1 DE 69632681 T DE69632681 T DE 69632681T DE 69632681 T DE69632681 T DE 69632681T DE 69632681 D1 DE69632681 D1 DE 69632681D1
- Authority
- DE
- Germany
- Prior art keywords
- beta
- lymphotoxin
- activating agent
- lhc
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37896895A | 1995-01-26 | 1995-01-26 | |
US378968 | 1995-01-26 | ||
PCT/US1996/001386 WO1996022788A1 (en) | 1995-01-26 | 1996-01-26 | LYMPHOTOXIN-α/β COMPLEXES AND ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69632681D1 true DE69632681D1 (de) | 2004-07-15 |
DE69632681T2 DE69632681T2 (de) | 2005-06-09 |
Family
ID=23495285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69632681T Expired - Fee Related DE69632681T2 (de) | 1995-01-26 | 1996-01-26 | Lymphotoxin-alpha/beta komplexe und antikörper gegen den lymphotoxin-beta rezeptor als agenzien gegen tumoren |
Country Status (25)
Country | Link |
---|---|
EP (2) | EP1407781A1 (de) |
JP (2) | JPH10513161A (de) |
KR (2) | KR100470739B1 (de) |
CN (3) | CN1589902A (de) |
AT (1) | ATE268604T1 (de) |
AU (1) | AU725351B2 (de) |
BG (1) | BG62599B1 (de) |
BR (1) | BR9606808A (de) |
CA (1) | CA2211443A1 (de) |
CZ (1) | CZ298711B6 (de) |
DE (1) | DE69632681T2 (de) |
DK (1) | DK0809510T3 (de) |
EA (1) | EA000096B1 (de) |
EE (1) | EE04453B1 (de) |
ES (1) | ES2220972T3 (de) |
FI (1) | FI119359B (de) |
HK (1) | HK1006356A1 (de) |
HU (1) | HUP9801746A3 (de) |
NO (1) | NO322744B1 (de) |
NZ (1) | NZ303405A (de) |
PL (1) | PL185364B1 (de) |
PT (1) | PT809510E (de) |
RO (1) | RO118634B1 (de) |
SK (1) | SK286497B6 (de) |
WO (1) | WO1996022788A1 (de) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5925351A (en) | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
US7118742B2 (en) * | 1997-07-07 | 2006-10-10 | La Jolla Institute For Allergy And Immunology | Ligand for herpes simplex virus entry mediator and methods of use |
US6140467A (en) * | 1997-07-07 | 2000-10-31 | La Jolla Institute For Allergy And Immunology | Ligand for herpes simplex virus entry mediator and methods of use |
US7060667B1 (en) | 1998-01-30 | 2006-06-13 | Biogen Idec Ma, Inc. | Treatment of follicular lymphomas using inhibitors of the LT pathway |
DE69931944T2 (de) | 1998-10-09 | 2007-02-08 | Biogen Idec Ma Inc., Cambridge | Umkehr des viral-induzierten systemischen schocks und des atemnotsyndroms durch blockierung des lymphotoxin-beta- aktivierungsweges |
EP1326897A2 (de) * | 2000-10-13 | 2003-07-16 | Biogen, Inc. | Humanisierte antikörper gegen lt-beta-r |
AU2003248782A1 (en) * | 2002-07-01 | 2004-01-19 | Biogen Idec Ma Inc. | Humanized anti-lymphotoxin beta receptor antibodies |
PL377611A1 (pl) * | 2002-12-20 | 2006-02-06 | Biogen Idec Ma Inc. | Czynniki dla receptora limfotoksyny beta w połączeniu z czynnikami chemioterapeutycznymi |
EP1583503A4 (de) * | 2002-12-20 | 2006-08-09 | Biogen Idec Inc | Polyvalente lymphotoxin-beta-rezeptor-agonisten und therapeutische verwendung dafür |
JP5091476B2 (ja) | 2003-06-27 | 2012-12-05 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 均質な抗体溶液の生成のための疎水性相互作用クロマトグラフィーまたはヒンジ領域改変の使用 |
WO2005092927A1 (en) | 2004-03-23 | 2005-10-06 | Biogen Idec Ma Inc. | Receptor coupling agents and therapeutic uses thereof |
WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
EP1764371A1 (de) * | 2005-04-25 | 2007-03-21 | Xantos Biomedicine AG | Agonistische Antikörper, welche an den LT-Beta-Rezeptor binden und dadurch Adipositas assoziierte Phänotypen modulieren, und deren Verwendung in der Therapie |
CN101073665B (zh) * | 2006-05-17 | 2014-11-26 | 上海复旦张江生物医药股份有限公司 | 淋巴毒素在制备增加化疗药物敏感性的药物中的应用 |
WO2008042436A2 (en) | 2006-10-03 | 2008-04-10 | Biogen Idec Ma Inc. | Biomarkers and assays for the treatment of cancer |
US8338376B2 (en) | 2006-10-20 | 2012-12-25 | Biogen Idec Ma Inc. | Compositions comprising variant LT-B-R-IG fusion proteins |
US8067375B2 (en) | 2006-10-20 | 2011-11-29 | Biogen Idec Ma Inc. | Treatment of demyelinating disorders with soluble lymphotoxin-β-receptor |
BRPI0913687A2 (pt) * | 2008-09-30 | 2015-10-13 | Genentech Inc | marcadores biológicos preditivos da resposta da artrite reumatóide aos antagonistas da linfotoxina |
IN2014CN04961A (de) * | 2011-12-05 | 2015-09-18 | Igenica Biotherapeutics Inc | |
IL308212A (en) | 2015-01-20 | 2024-01-01 | Igm Biosciences Inc | Tumor necrosis factor-α receptor binding molecules and their uses |
WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
JP2024508207A (ja) | 2020-12-02 | 2024-02-26 | ブイアイビー ブイゼットダブリュ | がんに対する組み合わせ治療におけるltbrアゴニスト |
WO2023198848A1 (en) | 2022-04-13 | 2023-10-19 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6124599A (ja) * | 1984-07-11 | 1986-02-03 | Kyowa Hakko Kogyo Co Ltd | 新規ヒトインタ−フエロン−rポリペプチド誘導体 |
JPS61277628A (ja) * | 1985-06-04 | 1986-12-08 | Asahi Chem Ind Co Ltd | 癌治療用白血球刺激材 |
US4770995A (en) * | 1985-08-29 | 1988-09-13 | New York Blood Center, Inc | Detection of the sensitivity of cells to the effects of tumor necrosis factor and lymphotoxin |
AU8228891A (en) * | 1990-06-27 | 1992-01-23 | Biogen, Inc. | Surface complexed lymphotoxin |
EP0672143B1 (de) * | 1992-12-04 | 2008-06-04 | Biogen Idec MA Inc. | Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon |
-
1996
- 1996-01-26 EE EE9700255A patent/EE04453B1/xx not_active IP Right Cessation
- 1996-01-26 JP JP8523078A patent/JPH10513161A/ja not_active Withdrawn
- 1996-01-26 CN CNA2004100070585A patent/CN1589902A/zh active Pending
- 1996-01-26 KR KR1019970705213A patent/KR100470739B1/ko not_active IP Right Cessation
- 1996-01-26 DK DK96906260T patent/DK0809510T3/da active
- 1996-01-26 RO RO97-01398A patent/RO118634B1/ro unknown
- 1996-01-26 DE DE69632681T patent/DE69632681T2/de not_active Expired - Fee Related
- 1996-01-26 KR KR10-2004-7015796A patent/KR100475492B1/ko not_active IP Right Cessation
- 1996-01-26 PT PT96906260T patent/PT809510E/pt unknown
- 1996-01-26 SK SK986-97A patent/SK286497B6/sk not_active IP Right Cessation
- 1996-01-26 CZ CZ0236197A patent/CZ298711B6/cs not_active IP Right Cessation
- 1996-01-26 NZ NZ303405A patent/NZ303405A/en not_active IP Right Cessation
- 1996-01-26 PL PL96321758A patent/PL185364B1/pl unknown
- 1996-01-26 BR BR9606808A patent/BR9606808A/pt not_active Application Discontinuation
- 1996-01-26 WO PCT/US1996/001386 patent/WO1996022788A1/en active IP Right Grant
- 1996-01-26 EA EA199700144A patent/EA000096B1/ru not_active IP Right Cessation
- 1996-01-26 AT AT96906260T patent/ATE268604T1/de not_active IP Right Cessation
- 1996-01-26 HU HU9801746A patent/HUP9801746A3/hu unknown
- 1996-01-26 CN CNB961922710A patent/CN1146442C/zh not_active Expired - Fee Related
- 1996-01-26 ES ES96906260T patent/ES2220972T3/es not_active Expired - Lifetime
- 1996-01-26 EP EP20030022584 patent/EP1407781A1/de not_active Withdrawn
- 1996-01-26 CA CA002211443A patent/CA2211443A1/en not_active Abandoned
- 1996-01-26 AU AU49704/96A patent/AU725351B2/en not_active Ceased
- 1996-01-26 EP EP96906260A patent/EP0809510B1/de not_active Expired - Lifetime
- 1996-01-26 CN CNA2006101007130A patent/CN1900116A/zh active Pending
-
1997
- 1997-07-22 NO NO19973385A patent/NO322744B1/no not_active IP Right Cessation
- 1997-07-25 FI FI973118A patent/FI119359B/fi active IP Right Grant
- 1997-08-26 BG BG101855A patent/BG62599B1/bg unknown
-
1998
- 1998-06-02 HK HK98104772A patent/HK1006356A1/xx not_active IP Right Cessation
-
2007
- 2007-03-12 JP JP2007062695A patent/JP2007169296A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69632681D1 (de) | Lymphotoxin-alpha/beta komplexe und antikörper gegen den lymphotoxin-beta rezeptor als agenzien gegen tumoren | |
Mohanam et al. | Modulation of in vitro invasion of human glioblastoma cells by urokinase-type plasminogen activator receptor antibody | |
DE69841164D1 (de) | Sphingosin-1-phosphat-lyase polypeptide, polynukleotide und modulierende mitteln, und verfahren zu deren verwendung | |
Aragane et al. | Involvement of dectin-2 in ultraviolet radiation-induced tolerance | |
EP0734264A4 (de) | Verbindungen die spezifisch an kolorektale krebszellen binden und verfahren fuerihre herstellung | |
IL128003A0 (en) | Therapeutic multispecific compounds comprised of anti-fcalpha receptor antibodies | |
NO20003534D0 (no) | Progesteronreseptor-modulatorforbindelser, farmasøytiske sammensetninger inneholdende disse og anvendelsen av forbindelsene | |
BR0313033A (pt) | anticorpos, anticorpos monoclonais, linhagens de células de hibridoma, anticorpos receptores de anti-taci isolados, anticorpos anti -taci, métodos de modulação da atividade biológica | |
YU83600A (sh) | Adenozin a3 receptorski modulatori | |
DE69737684D1 (de) | Präzise wirksamkeitsbestimmungsmethode für wirkstoffe einschliesslich chemotherapeutika | |
Thomas et al. | DNA cross-linking by in vivo treatment with 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea of sensitive and resistant human colon carcinoma xenografts in nude mice | |
DK0914345T3 (da) | Antistoffer, som binder til monocyt-kemoattraktant-protein-1-receptor (MCP-1-receptor) (CCR2) | |
AU3376297A (en) | Human thyrotropin receptor compositions and use thereof | |
UA42806C2 (uk) | Система для одночасного трансдермального введення кількох активних начал | |
DE69029812D1 (de) | Elemente für retinsäureantwortzusammensetzung und nachweisverfahren | |
GR3025698T3 (en) | NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES. | |
WO1997041225A3 (en) | Mammalian mixed lymphocyte receptors, chemokine receptors [mmlr-ccr] | |
Horton et al. | Reciprocal cross-resistance in human rhabdomyosarcomas selected in vivo for primary resistance to vincristine and L-phenylalanine mustard | |
Gibson et al. | Combined effects of streptozotocin and mitozolomide against four human cell lines of the Mer+ phenotype | |
ATE404676T1 (de) | Prostat-spezifisches-antigenformen und verfahren zu ihrer bestimmung | |
US10947596B2 (en) | Compositions and methods for identification, assessment, prevention, and treatment of cancer using NFS1 biomarkers and modulators | |
Hayashi et al. | Energy-dependent endocytosis in eythrocyte ghosts: III. Hydrophobic character of maleimide inactivation sites of ATPase and of endocytosis | |
Rosewicz et al. | The amphicrine pancreatic cell line AR42J: a model system for combined studies on exocrine and endocrine secretion | |
DK0943014T3 (da) | Fremgangsmåder til diagnosticering af glaukom og opdagelse af antiglaukome lægemidler | |
Haukaas et al. | Effect of diethylstilbestrol and estramustine phosphate (estracyt®) on delayed hypersensitivity response to oxazolone in male mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: BIOGEN IDEC MA INC., CAMBRIDGE, MASS., US |
|
8339 | Ceased/non-payment of the annual fee |